A 66-year-old Japanese woman was referred to us because of severe anemia and fever and presented at our hospital. She was eventually diagnosed as having acute myeloblastic leukemia (AML; M0) with non-Hodgkin lymphoma (NHL). We investigated the therapeutic efficacy of L-asparaginase (L-Asp), vincristine and prednisolone for both her AML and NHL. Asparagine synthetase (AS) activity in her AML blast cells was undetectable. A lymph node biopsy specimen revealed NHL of the marginal zone B cell type. Complete remission (CR) of AML and NHL was achieved. CR of the AML lasted for 18 months without further consolidation therapy. We conclude that L-Asp can be an effective drug for the treatment of AML in which blasts are negative for AS.

Rosner F, Grunwald H: Hodgkin’s disease and acute leukemia: report of eight cases and review of the literature. Am J Med 1975;58:339–353.
Canellos GP, DeVita VT, Arseneau JC, Whan-Peng J, Johnson REC: Second malignancies complicating Hodgkin’s disease in remission. Lancet 1975;1(7913):947–949.
Grunwald HW, Rosner F: Acute myeloid leukemia following treatment of Hodgkin’s disease. Cancer 1982;50:676–683.
Zarrabi MH, Rosner F, Bennet JM: Non-Hodgkin’s lymphoma and acute myeloblastic leukemia. Report of 12 cases and review of the literature. Cancer 1979;44:1070–1080.
Greene MH, Young RC, Merrill JM, DeVita VT: Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin’s lymphoma. Cancer Res 1983;43:1891–1898.
Super HJG, McCabe NR, Thirman MJ, Larson RA, Le Beau MM, Pedersen-Bjergaard J, Phillip P, Diaz MO, Rowley JD: Rearrangement of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 1993;82:3705–3711.
Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB: The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 1979;301:743–748.
Stern N, Shemesh J, Ramot B: Chronic lymphatic leukemia terminating in acute myeloid leukemia: review of the literature. Cancer 1981;47:1849–1851.
Kitoh T, Sawada M, Shirahase H, Hamahata K, Usami I, Ying-Wei L, Akiyama Y, Kubota M, Schuster SM: Asparagine synthetase protein expression in leukemia cells: application of L-asparaginase treatment for leukemia. Blood 1998;92(suppl 1):400a.
Ota K, Ogawa N: Randomized controlled study of chemoimmunotherapy with bestatin of acute nonlymphocytic leukemia in adults. Biomed Pharmacother 1990;44:93–102.
Kapadia SB, Kaplan SS: Simultaneous occurrence of non-Hodgkin’s lymphoma and acute myelomonocytic leukemia. Cancer 1978;38:2257–2260.
Kjeldsberg CR, Nathwani BN, Rappaport H: Acute myeloblastic leukemia developing in patients with mediastinal lymphoblastic lymphoma. Cancer 1979;44:2316–2323.
Dumont I, Mayer M, Fievez M, Neve P: Acute myeloblastic leukemia occurring with an extranodal lymphoma: an unusual association. Acta Clin Belg 1983;38:128–133.
Jaalouk G, Avvisati G, Latagliata R, Pacchiarotti A, Pulsoni A, Mecarocci S, Malagnino F: Simultaneous occurrence of large B-cell non-Hodgkin lymphoma and myelodysplastic syndrome rapidly evolving into acute myeloblastic leukemia. Leuk Lymphoma 1996;21:339–341.
Saxenia A, Sheridan DP, Card RT, McPeek AM, Mewdell CC, Skinnider LF: Biologic and clinical significance of CD7 expression in acute myeloid leukemia. Am J Hematol 1998;58:278–284.
Ogata K, Yokose N, Shioi Y, Ishida Y, Tomiyama J, Hamaguchi H, Yagasaki F, Bessyo M, Sakamaki H, Dan K, Kuriya S: Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia. Br J Haematol 2001;115:612–615.
Yamamoto K, Nagata K, Hamaguchi H: A new case of CD7-positive acute myeloblastic leukemia with trisomy 21 as a sole acquired abnormality. Cancer Genet Cytogenet 2002;133:183–184.
Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR, Schiffer CA, Bloomfield CD: Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 1997;90:1643–1648.
Raspadori D, Damiani D, Lenoci M, Rondelli D, Testoni N, Nardi G, Sestigiani C, Mariotti C, Birtolo S, Tozzi M, Lauria F: CD56 antigen expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 2001;15:1161–1164.
Suzuki R, Murata M, Kami M, Ohtake S, Asou N, Kodera Y, Tomonaga M, Masaki Y, Kusumoto S, Takeuchi J, Matsuda S, Hirai H, Yorimitsu S, Hamajima N, Seto M, Shimoyama M, Ohno R, Morishima Y, Nakamura S: Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0. Int J Hematol 2003;77:482–489.
Cruse JM, Lewis RE, Pierce S, Lam J, Tadros Y: Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias. Exp Mol Pathol 2005;79:39–41.
Law IP, Blom J: Second malignancies in patients with multiple myeloma. Oncology 1977;34:20–24.
Grulich AE, Li Y, McDonald A, Correl PK, Law MG, Kaldor JM: Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002;16:1155–1161.
Capizzi RL, Bertino JR, Skeel RT: L-Asparaginase: clinical, biochemical, pharmacological and immunological status. Ann Intern Med 1971;74:893–901.
Haskell CM, Canellos GP, Leventhal BG, Carbone PP, Block JB: L-Asparaginase resistance in human leukemia – asparagine synthetase. Biochem Pharmacol 1969;18:2578–2580.
Aleskog A, Larsson R, Hoglund M, Kristensen J, Nygren P, Lindhagen E: In vitro drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia. Anticancer Drugs 2005;16:277–283.
Clarkson B, Krakoff I, Burchenal J, Karnofsky D, Golbey R, Dowling M, Oettgen H, Lipton A: Clinical results of treatment with E. coliL-asparaginase in adults with leukemia, lymphoma and solid tumors. Cancer 1970;25:279–305.
Capizzi RL, Davis R, Powell B, Cuttner J, Ellison RR, Cooper RR, Dillman R, Major WB, Dupre E, Mcintyre OR: Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia – a Cancer and Leukemia Group B Study. J Clin Oncol 1988;6:499–508.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.